Do analysts prefer IMRN or BGM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immuron 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, IMRN or BGM?

BGM Group has higher revenue and earnings than Immuron. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immuron $4.72M 2.18 -$3.38M N/A N/A BGM Group $25.10M 1.33 -$1.44M N/A N/A

Is IMRN or BGM more profitable?

Company Net Margins Return on Equity Return on Assets Immuron N/A N/A N/A BGM Group N/A N/A N/A

Do analysts recommend ACTU or IMRN?

Actuate Therapeutics presently has a consensus price target of $17.50, suggesting a potential upside of 1,322.76%. Given Actuate Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Actuate Therapeutics is more favorable than Immuron. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actuate Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Immuron 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, ACTU or IMRN?

Immuron has higher revenue and earnings than Actuate Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Actuate Therapeutics N/A N/A -$22.23M -$0.97 N/A Immuron $4.72M 2.18 -$3.38M N/A N/A

Is ACTU or IMRN more profitable?

Immuron's return on equity of 0.00% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Actuate Therapeutics N/A -430.93% -180.86% Immuron N/A N/A N/A

Do analysts rate IMRN or ALGS?

Aligos Therapeutics has a consensus target price of $38.50, indicating a potential upside of 468.69%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aligos Therapeutics is more favorable than Immuron. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immuron 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aligos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86

Which has better earnings and valuation, IMRN or ALGS?

Immuron has higher revenue and earnings than Aligos Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immuron $4.72M 2.18 -$3.38M N/A N/A Aligos Therapeutics $2.19M 19.14 -$24.19M -$8.69 N/A

Does the media favor IMRN or ALGS?

In the previous week, Aligos Therapeutics had 2 more articles in the media than Immuron. MarketBeat recorded 5 mentions for Aligos Therapeutics and 3 mentions for Immuron. Immuron's average media sentiment score of 0.90 beat Aligos Therapeutics' score of 0.16 indicating that Immuron is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immuron 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aligos Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate IMRN or SNTI?

Senti Biosciences has a consensus price target of $10.00, indicating a potential upside of 900.00%. Given Senti Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Senti Biosciences is more favorable than Immuron. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immuron 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Senti Biosciences 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75

Which has stronger valuation & earnings, IMRN or SNTI?

Immuron has higher revenue and earnings than Senti Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immuron $4.72M 2.18 -$3.38M N/A N/A Senti Biosciences $38K 819.61 -$61.44M -$1.92 N/A

Is IMRN or SNTI more profitable?

Immuron's return on equity of 0.00% beat Senti Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Immuron N/A N/A N/A Senti Biosciences N/A -532.05% -103.35%

Do analysts rate IMRN or HCWB?

HCW Biologics has a consensus target price of $30.00, suggesting a potential upside of 546.55%. Given HCW Biologics' stronger consensus rating and higher probable upside, analysts clearly believe HCW Biologics is more favorable than Immuron. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immuron 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 HCW Biologics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings & valuation, IMRN or HCWB?

Immuron has higher revenue and earnings than HCW Biologics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immuron $4.72M 2.18 -$3.38M N/A N/A HCW Biologics $50K 148.48 -$7.96M -$56.75 N/A

Is IMRN or HCWB more profitable?

Immuron has a net margin of 0.00% compared to HCW Biologics' net margin of -34.73%. Immuron's return on equity of 0.00% beat HCW Biologics' return on equity. Company Net Margins Return on Equity Return on Assets Immuron N/A N/A N/A HCW Biologics -34.73% -486.87% -29.19%

Immuron (IMRN) Competitors

$1.26 -0.07 (-5.26%)

Closing price 07/9/2026 04:00 PM Eastern

Extended Trading

$1.28 +0.02 (+1.98%)

As of 07/9/2026 07:17 PM Eastern

Compare

IMRN vs. BGM, ACTU, ALGS, SNTI, and HCWB

Should you buy Immuron stock or one of its competitors? MarketBeat compares Immuron with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Immuron include BGM Group (BGM), Actuate Therapeutics (ACTU), Aligos Therapeutics (ALGS), Senti Biosciences (SNTI), and HCW Biologics (HCWB). These companies are all part of the "med - biomed/gene" industry.

How does Immuron compare to BGM Group?

Immuron (NASDAQ:IMRN) and BGM Group (NASDAQ:BGM) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

In the previous week, Immuron had 3 more articles in the media than BGM Group. MarketBeat recorded 3 mentions for Immuron and 0 mentions for BGM Group. Immuron's average media sentiment score of 0.90 beat BGM Group's score of 0.75 indicating that Immuron is being referred to more favorably in the media.

Company	Overall Sentiment
Immuron	Positive
BGM Group	Positive

Immuron has a beta of 1.16, meaning that its share price is 16% more volatile than the broader market. Comparatively, BGM Group has a beta of 1.78, meaning that its share price is 78% more volatile than the broader market.

BGM Group has higher revenue and earnings than Immuron.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuron	$4.72M	2.18	-$3.38M	N/A	N/A
BGM Group	$25.10M	1.33	-$1.44M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuron	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Immuron	N/A	N/A	N/A
BGM Group	N/A	N/A	N/A

0.1% of Immuron shares are held by institutional investors. 7.0% of Immuron shares are held by insiders. Comparatively, 58.7% of BGM Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Immuron and BGM Group tied by winning 4 of the 8 factors compared between the two stocks.

How does Immuron compare to Actuate Therapeutics?

Actuate Therapeutics (NASDAQ:ACTU) and Immuron (NASDAQ:IMRN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, risk and dividends.

0.1% of Immuron shares are held by institutional investors. 58.0% of Actuate Therapeutics shares are held by insiders. Comparatively, 7.0% of Immuron shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Actuate Therapeutics presently has a consensus price target of $17.50, suggesting a potential upside of 1,322.76%. Given Actuate Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Actuate Therapeutics is more favorable than Immuron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Immuron	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Actuate Therapeutics has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market. Comparatively, Immuron has a beta of 1.16, suggesting that its share price is 16% more volatile than the broader market.

Immuron's return on equity of 0.00% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actuate Therapeutics	N/A	-430.93%	-180.86%
Immuron	N/A	N/A	N/A

Immuron has higher revenue and earnings than Actuate Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.97	N/A
Immuron	$4.72M	2.18	-$3.38M	N/A	N/A

In the previous week, Immuron had 3 more articles in the media than Actuate Therapeutics. MarketBeat recorded 3 mentions for Immuron and 0 mentions for Actuate Therapeutics. Immuron's average media sentiment score of 0.90 beat Actuate Therapeutics' score of 0.00 indicating that Immuron is being referred to more favorably in the news media.

Company	Overall Sentiment
Actuate Therapeutics	Neutral
Immuron	Positive

Summary

Immuron beats Actuate Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Immuron compare to Aligos Therapeutics?

Immuron (NASDAQ:IMRN) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

Aligos Therapeutics has a consensus target price of $38.50, indicating a potential upside of 468.69%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aligos Therapeutics is more favorable than Immuron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuron	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Immuron has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,919.68%. Immuron's return on equity of 0.00% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuron	N/A	N/A	N/A
Aligos Therapeutics	-1,919.68%	-139.47%	-90.88%

Immuron has higher revenue and earnings than Aligos Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuron	$4.72M	2.18	-$3.38M	N/A	N/A
Aligos Therapeutics	$2.19M	19.14	-$24.19M	-$8.69	N/A

0.1% of Immuron shares are owned by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are owned by institutional investors. 7.0% of Immuron shares are owned by insiders. Comparatively, 7.8% of Aligos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Aligos Therapeutics had 2 more articles in the media than Immuron. MarketBeat recorded 5 mentions for Aligos Therapeutics and 3 mentions for Immuron. Immuron's average media sentiment score of 0.90 beat Aligos Therapeutics' score of 0.16 indicating that Immuron is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immuron	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aligos Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immuron has a beta of 1.16, suggesting that its share price is 16% more volatile than the broader market. Comparatively, Aligos Therapeutics has a beta of 2.26, suggesting that its share price is 126% more volatile than the broader market.

Summary

Aligos Therapeutics beats Immuron on 9 of the 15 factors compared between the two stocks.

How does Immuron compare to Senti Biosciences?

Immuron (NASDAQ:IMRN) and Senti Biosciences (NASDAQ:SNTI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings and media sentiment.

0.1% of Immuron shares are owned by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are owned by institutional investors. 7.0% of Immuron shares are owned by company insiders. Comparatively, 3.1% of Senti Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Immuron has higher revenue and earnings than Senti Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuron	$4.72M	2.18	-$3.38M	N/A	N/A
Senti Biosciences	$38K	819.61	-$61.44M	-$1.92	N/A

In the previous week, Immuron had 3 more articles in the media than Senti Biosciences. MarketBeat recorded 3 mentions for Immuron and 0 mentions for Senti Biosciences. Immuron's average media sentiment score of 0.90 beat Senti Biosciences' score of 0.67 indicating that Immuron is being referred to more favorably in the media.

Company	Overall Sentiment
Immuron	Positive
Senti Biosciences	Positive

Immuron has a beta of 1.16, suggesting that its share price is 16% more volatile than the broader market. Comparatively, Senti Biosciences has a beta of 2.04, suggesting that its share price is 104% more volatile than the broader market.

Senti Biosciences has a consensus price target of $10.00, indicating a potential upside of 900.00%. Given Senti Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Senti Biosciences is more favorable than Immuron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuron	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Immuron's return on equity of 0.00% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuron	N/A	N/A	N/A
Senti Biosciences	N/A	-532.05%	-103.35%

Summary

Immuron and Senti Biosciences tied by winning 7 of the 14 factors compared between the two stocks.

How does Immuron compare to HCW Biologics?

Immuron (NASDAQ:IMRN) and HCW Biologics (NASDAQ:HCWB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership and profitability.

HCW Biologics has a consensus target price of $30.00, suggesting a potential upside of 546.55%. Given HCW Biologics' stronger consensus rating and higher probable upside, analysts clearly believe HCW Biologics is more favorable than Immuron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuron	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Immuron has a net margin of 0.00% compared to HCW Biologics' net margin of -34.73%. Immuron's return on equity of 0.00% beat HCW Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuron	N/A	N/A	N/A
HCW Biologics	-34.73%	-486.87%	-29.19%

Immuron has a beta of 1.16, suggesting that its share price is 16% more volatile than the broader market. Comparatively, HCW Biologics has a beta of 2.29, suggesting that its share price is 129% more volatile than the broader market.

0.1% of Immuron shares are held by institutional investors. Comparatively, 3.0% of HCW Biologics shares are held by institutional investors. 7.0% of Immuron shares are held by insiders. Comparatively, 9.1% of HCW Biologics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Immuron has higher revenue and earnings than HCW Biologics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuron	$4.72M	2.18	-$3.38M	N/A	N/A
HCW Biologics	$50K	148.48	-$7.96M	-$56.75	N/A

In the previous week, Immuron had 3 more articles in the media than HCW Biologics. MarketBeat recorded 3 mentions for Immuron and 0 mentions for HCW Biologics. Immuron's average media sentiment score of 0.90 beat HCW Biologics' score of 0.00 indicating that Immuron is being referred to more favorably in the media.

Company	Overall Sentiment
Immuron	Positive
HCW Biologics	Neutral

Summary

Immuron and HCW Biologics tied by winning 7 of the 14 factors compared between the two stocks.

Get Immuron News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMRN vs. The Competition

Export

Metric	Immuron	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$10.86M	$3.78B	$6.93B	$12.49B
Dividend Yield	N/A	2.18%	2.68%	7.79%
P/E Ratio	N/A	21.70	27.39	24.62
Price / Sales	2.18	328.99	549.66	113.75
Price / Cash	N/A	145.39	48.45	59.17
Price / Book	1.62	8.62	11.02	6.46
Net Income	-$3.38M	$23.85M	$3.57B	$331.60M
7 Day Performance	14.55%	0.96%	0.41%	0.33%
1 Month Performance	7.69%	13.39%	6.54%	2.51%
1 Year Performance	-28.81%	55.25%	29.65%	21.59%

Immuron Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMRN Immuron	0.9341 of 5 stars	$1.26 -5.3%	N/A	-28.6%	$10.86M	$4.72M	N/A	N/A
BGM BGM Group	0.7486 of 5 stars	$0.36 -3.2%	N/A	-96.5%	$34.61M	$25.10M	N/A	298	Gap Up
ACTU Actuate Therapeutics	1.8018 of 5 stars	$1.44 -5.7%	$17.50 +1,112.8%	-81.4%	$34.53M	N/A	N/A	10	Gap Down
ALGS Aligos Therapeutics	2.9027 of 5 stars	$5.48 -5.1%	$38.50 +603.2%	-21.8%	$33.89M	$2.19M	N/A	90	News Coverage
SNTI Senti Biosciences	2.8033 of 5 stars	$1.07 -2.7%	$10.00 +834.6%	-57.4%	$33.33M	$20K	N/A	4

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMRN) was last updated on 7/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immuron (IMRN) Competitors

IMRN vs. BGM, ACTU, ALGS, SNTI, and HCWB

How does Immuron compare to BGM Group?

Summary

How does Immuron compare to Actuate Therapeutics?

Summary

How does Immuron compare to Aligos Therapeutics?

Summary

How does Immuron compare to Senti Biosciences?

Summary

How does Immuron compare to HCW Biologics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMRN vs. The Competition

Immuron Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immuron (IMRN) Competitors

IMRN vs. BGM, ACTU, ALGS, SNTI, and HCWB

How does Immuron compare to BGM Group?

Does the media refer more to IMRN or BGM?

Which has more risk and volatility, IMRN or BGM?

Which has stronger earnings & valuation, IMRN or BGM?

Do analysts prefer IMRN or BGM?

Is IMRN or BGM more profitable?

Do insiders and institutionals believe in IMRN or BGM?

Summary

How does Immuron compare to Actuate Therapeutics?

Do insiders & institutionals hold more shares of ACTU or IMRN?

Do analysts recommend ACTU or IMRN?

Which has more risk and volatility, ACTU or IMRN?

Is ACTU or IMRN more profitable?

Which has preferable earnings and valuation, ACTU or IMRN?

Does the media prefer ACTU or IMRN?

Summary

How does Immuron compare to Aligos Therapeutics?

Do analysts rate IMRN or ALGS?

Is IMRN or ALGS more profitable?

Which has better earnings and valuation, IMRN or ALGS?

Do institutionals and insiders believe in IMRN or ALGS?

Does the media favor IMRN or ALGS?

Which has more volatility & risk, IMRN or ALGS?

Summary

How does Immuron compare to Senti Biosciences?

Do insiders and institutionals believe in IMRN or SNTI?

Which has stronger valuation & earnings, IMRN or SNTI?

Does the media refer more to IMRN or SNTI?

Which has more volatility & risk, IMRN or SNTI?

Do analysts rate IMRN or SNTI?

Is IMRN or SNTI more profitable?

Summary

How does Immuron compare to HCW Biologics?

Do analysts rate IMRN or HCWB?

Is IMRN or HCWB more profitable?

Which has more risk and volatility, IMRN or HCWB?

Do institutionals & insiders have more ownership in IMRN or HCWB?

Which has better earnings & valuation, IMRN or HCWB?

Does the media refer more to IMRN or HCWB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMRN vs. The Competition

Immuron Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools